拓扑异构酶Ⅱ在神经胶质瘤中的研究进展  

Research progress of topoisomeraseⅡin glioma

作　　者：陈洋 汪东亮 孙雯雯 阴鲁鑫 徐伟文 CHEN Yang;WANG Dongliang;SUN Wenwen;YIN Luxin;XU Weiwen(The First People’s Hospital of Suqian,Suqian 223800,China;Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,China)

机构地区：[1]宿迁市第一人民医院,江苏宿迁223800 [2]徐州医科大学附属医院,江苏徐州221000

出　　处：《中国实用神经疾病杂志》2023年第8期1037-1040,共4页Chinese Journal of Practical Nervous Diseases

基　　金：中国博士后科学基金(编号:2015M571821)。

摘　　要：目前癌症基因检测作用于帮助患者判断预后和指导靶向治疗,逐渐成为国内外肿瘤诊疗的发展趋势和关注焦点。胶质瘤是源自神经上皮最常见的脑恶性肿瘤,近年来发现DNA拓扑异构酶Ⅱ(TOPⅡ)作为人脑胶质瘤的标志物,与该肿瘤密切相关,为此本文阐述了TOPⅡ在胶质瘤中的表达及与肿瘤细胞增殖率和预后的研究进展,对其深入探究,有望为预测胶质瘤患者预后、指导化疗用药和延缓患者生存期限提供理论支持和有效指导。At present,cancer gene detection can help patients to judge the prognosis and guide targeted therapy,which has gradually become the development trend and focus of cancer diagnosis and treatment at home and abroad.Glioma is the most common brain malignant tumor originating from neuroepithelium.In recent years,DNA topoisomeraseⅡ(TOPⅡ),as a marker of human glioma,has been found to be closely related to this tumor.Therefore,this paper describes the expression of TOPⅡin glioma and the research progress on its relationship with tumor cell proliferation rate and prognosis.In-depth exploration of this method is expected to provide theoreti⁃cal support and effective guidance for predicting the prognosis of glioma patients,guiding chemotherapy drugs and delaying the survival of patients.

关 键 词：胶质瘤 拓扑异构酶Ⅱ 增殖率 恶性程度 预后 

分 类 号：R739.4[医药卫生—肿瘤]